News | September 05, 2025
Quotient Sciences and CPI join forces to accelerate RNA drug development
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
The positive benefit-risk profile of vericiguat in its approved indication in patients with HFrEF following a recent heart failure event based on the pivotal Phase III VICTORIA trial remains unchanged
Zilebesiran, a potential best-in-disease RNAi anti-hypertensive with twice-yearly subcutaneous dosing, demonstrated encouraging safety when combined with two or more antihypertensives
The sudden subsequent decision to suspend IXCHIQ is based on updated VAERS data
Triggering global regulatory submissions this year for the treatment of obesity
Collaboration reinforces Boehringer Ingelheim’s expertise in microbial contract development and manufacturing
The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
Subscribe To Our Newsletter & Stay Updated
